The US Food and Drug Administration has taken steps to address the shortage of critically needed cancer drugs by allowing for the temporary importation into the US of one product that the agency has not yet approved and by speeding up its review and approval of another product1.
In addition, the agency has published for comment a draft guidance for industry that details the agency's expectations for mandatory and voluntary notifications of issues
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?